Positive updated results from Aeterna Zentaris' AEZS-108 Phase 1 trial on CRPC

Aeterna Zentaris Inc. today reported positive updated results for the Phase 1 portion of its ongoing Phase 1/2 study in castration- and taxane-resistant prostate cancer (CRPC) with AEZS-108 (zoptarelin doxorubicin), the Company's targeted cytotoxic l..

Original Article: Positive updated results from Aeterna Zentaris' AEZS-108 Phase 1 trial on CRPC

 Channels 65 Associated Channels

• Antibody Drug Conjugates ADC

  The humanized anti-Her2 monoclonal antibody Herceptin (trastuzumab) has become the mainstay in the treatment of Her2-positive breast cancer. Combining trastuzumab with the potent cytotoxic DM1 via a s...

• Ovulatory phase

• Luteal phase

• Follicular phase

• Clinical Trials Phase News

  Clinical trials involving new drugs are commonly classified into four phases. Each phase of the drug approval process is treated as a separate clinical trial. The drug-development process will norma...

• Noninvasive positive pressure ventilation NIPPV

• Acute Phase Reactants

• Her2 Receptor Antagonists

  Targeted treatment of Her2-positive breast cancer with the anti-Her2 antibody trastuzumab has become an example of successful personalized medicine. The commercial success of Herceptin (trastuzumab)...

• The Asymptomatic Patient With Abnormal Laboratory Test Results

• Heat shock protein 90 Hsp90

  Inhibition of heat shock protein 90 (Hsp90) results in the degradation of oncoproteins that drive malignant progression, inducing cell death, making Hsp90 a target of substantial interest for cancer...

Associated Content for this Article

• View Related Companies
• View Related Events
• View Related Clinical Trials
• View Related PubMed Articles
• View Related Medications

Latest Biotechnology, Pharmaceutical and Healthcare News

Searches Linking to this Page

None